LUTRONIC Corporation   Report issue

For profit Phase 4
Founded: Goyang-si Korea, Republic of (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2016
NCT03040089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

LUTRONIC Corporation

Active Ingredients

Drugs in Phase 4 Trials (1)

ranibizumab (lucentis) (1 trial)

Drugs in Other Trials (1)

hydroquinone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 4)

Macular Edema (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2